Redefining Soft Tissue Intelligence
“To bring precision, clarity, and science to human motion—empowering employers, clinicians, and individuals to better manage injury, accelerate recovery, and unlock higher performance.”
Precision Motion Health (PMH) is the Soft Tissue Intelligence Platform—uniting functional measurement, biomechanics, and AI analytics to bring greater clarity and confidence to every stage of motion care.
By connecting science, technology, and human insight, PMH helps organizations support their teams and achieve better outcomes across prevention, assessment, and recovery.
Our Journey
Founded in 2012 as Emerge Diagnostics, Precision Motion Health (PMH) has been at the forefront of soft-tissue innovation. In August 2024, the company rebranded to Precision Motion Health to better reflect its mission of delivering objective, technology-driven musculoskeletal care powered by data, diagnostics, and precision.
The rebranding underscores PMH’s commitment to innovation and its focus on precision in musculoskeletal health—moving beyond diagnostics toward integrated intelligence that improves outcomes and accelerates recovery. Our patented Electromyographic Functional Assessment (EFA) technology remains the foundation of this mission, combining electromyography, range-of-motion, and force measurement into one objective, FDA-cleared system.
Over more than a decade, our technology has helped leading employers in transportation, logistics, and manufacturing save over $150 million in claim costs and keep more than 200,000 workers healthy and productive. Today, PMH is evolving from a diagnostic provider into a full-scale Soft Tissue Intelligence Platform—integrating posture, movement, and recovery analytics powered by AI to predict risk, personalize care, and optimize return-to-work outcomes.
Our Vision
To build the world’s most trusted soft-tissue intelligence ecosystem—one that bridges data, science, and human motion to enable better outcomes.
- AI Integration: Leveraging machine learning alongside decades of clinical expertise to interpret motion data with precision and consistency.
- Objective Insight: Bringing clarity and intelligent analytics to the subjective nature of soft-tissue assessment.
- Human-Centered Design: Empowering clinicians, employers, and individuals with intuitive, evidence-based tools that enhance understanding and collaboration.
Validated Impact
30-60% reduction in frequency and duration of soft tissue claims
$150M + in improved care and unnecessary costs and interventions
200K + employees supported through our programs
Leadership
Guided by a team combining healthcare innovation, technology, and operational excellence.
Chief Executive Officer
Founder of Omzi Medical Solutions and long-time PMH partner, Ahmed brings a decade of nationwide clinical operations experience in workers’ comp and occupational health. He is leading PMH’s next phase of expansion and intelligence integration.
Vice President of Operations
Sheila drives PMH’s operational excellence and client ROI, developing the Tele-EFA program and strategic relationships with top employers such as J.B. Hunt and C.R. England.
Medical Director
Renowned neurosurgeon and EFA pioneer, Dr. Tomecek has been instrumental in clinical validation and regulatory recognition of PMH’s technology within the AMA and OSHA frameworks.
Chief Scientific Officer
Devin serves as lead scientist and subject-matter expert in electromyography (EMG) for PMH, bringing decades of experience in evidence-based muscle-function analysis and movement, to ensure PMH’s technology and methods remain accurate, reliable, and applicable.
Chief Technology Officer
Sid leads the modernization of PMH’s technology stack and data infrastructure. With extensive SaaS experience serving Fortune 500 clients, he is driving platform scalability, data security, and AI enablement.
Director of Post-Assessments
Vanessa oversees program execution and clinical coordination nationwide, ensuring high-quality testing and client satisfaction through every assessment touchpoint.
Director of Pre-Assessments
Chanel leads frontline operations and quality control for pre-assessment protocols, supporting PMH’s commitment to precision and patient care excellence.
Patents & Innovation
PMH holds a strong portfolio of U.S. and international patents covering its EFA systems and wireless diagnostic methods — including U.S. Patent Nos. 8,117,047, 8,535,224, and 8,568,312 — as well as a method for objectively determining removal of surgically-implanted hardware (U.S. Publication 2015/0126893 A1). Ongoing applications extend into virtual triage and AI-driven motion analysis, cementing PMH’s leadership in soft-tissue innovation.